Clinical educator Rian Seo argues why ‘training room myths’ regarding leftover PNs can compromise sterility, ethical practice and regulatory compliance
The UK aesthetics market is currently defined by a ‘regenerative gold rush,’ with recent specialty data indicating a 25% year-on-year surge in demand for biostimulatory treatments.¹ Polynucleotides (PNs) have moved from a niche South Korean import to a cornerstone of British clinical practice, largely due to a consumer shift away from ‘over-filled’ aesthetics toward cellular-level repair.² However, this rapid scaling has created a dangerous gap between commercial enthusiasm and clinical discipline.
When attending clinical education sessions, I frequently hear the same piece of advice, “If you have product left in the syringe, don’t bin it; just microneedle it into the skin as an add-on.” It is often presented as sensible product stewardship. However, I believe this is a scientific fallacy that undermines the integrity of the treatment and blurs the line between evidence-based medicine…
